tetano
Editor, Senior Moderator
iScience
. 2024 Jan 17;27(2):108887.
doi: 10.1016/j.isci.2024.108887. eCollection 2024 Feb 16. UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease
Chang Yi Wang[SUP] 1 [/SUP], Be-Sheng Kuo[SUP] 1 [/SUP], Yu-Hsiang Lee[SUP] 1 [/SUP], Yu-Hsin Ho[SUP] 1 [/SUP], Yi-Hua Pan[SUP] 1 [/SUP], Ya-Ting Yang[SUP] 1 [/SUP], Hsi-Chi Chang[SUP] 1 [/SUP], Lin-Fang Fu[SUP] 1 [/SUP], Wen-Jiun Peng[SUP] 1 [/SUP]
Affiliations
UB-612 pan-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine targets the monomeric Spike S1-receptor binding domain (RBD) subunit protein along with five sequence-conserved T cell epitopes found on Spike S2 and non-Spike M and N proteins. UB-612 vaccination safely induces potent, broad, and long-lasting immunity against SARS-CoV-2. A phase-2 trial-extended observational study during the Omicron BA.2-/BA.5-dominated outbreak was conducted to investigate UB-612's protective effect against COVID-19 hospitalization and intensive care unit (ICU) admission (H-ICU). Additionally, memory viral-neutralizing titer and T cell immunity behind disease protection were explored. No cases of H-ICU were reported beyond 14 months post-second dose or beyond 10 months post-booster (third dose). The positive outcome correlates with strong cytotoxic CD8 T cell immunity, in line with the results of an ongoing phase-3 heterologous booster trial showing that UB-612 can enhance anti-BA.5 seroconversion rate and viral-neutralizing titer for mRNA, adeno-vectored, and virus-inactivated vaccine platforms. The UB-612 multitope vaccine may serve as an effective primer and booster for those at risk of SARS-CoV-2 infection.
Keywords: Cell biology; Immunity; Microbiology.
. 2024 Jan 17;27(2):108887.
doi: 10.1016/j.isci.2024.108887. eCollection 2024 Feb 16. UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease
Chang Yi Wang[SUP] 1 [/SUP], Be-Sheng Kuo[SUP] 1 [/SUP], Yu-Hsiang Lee[SUP] 1 [/SUP], Yu-Hsin Ho[SUP] 1 [/SUP], Yi-Hua Pan[SUP] 1 [/SUP], Ya-Ting Yang[SUP] 1 [/SUP], Hsi-Chi Chang[SUP] 1 [/SUP], Lin-Fang Fu[SUP] 1 [/SUP], Wen-Jiun Peng[SUP] 1 [/SUP]
Affiliations
- PMID: 38318376
- PMCID: PMC10839960
- DOI: 10.1016/j.isci.2024.108887
UB-612 pan-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine targets the monomeric Spike S1-receptor binding domain (RBD) subunit protein along with five sequence-conserved T cell epitopes found on Spike S2 and non-Spike M and N proteins. UB-612 vaccination safely induces potent, broad, and long-lasting immunity against SARS-CoV-2. A phase-2 trial-extended observational study during the Omicron BA.2-/BA.5-dominated outbreak was conducted to investigate UB-612's protective effect against COVID-19 hospitalization and intensive care unit (ICU) admission (H-ICU). Additionally, memory viral-neutralizing titer and T cell immunity behind disease protection were explored. No cases of H-ICU were reported beyond 14 months post-second dose or beyond 10 months post-booster (third dose). The positive outcome correlates with strong cytotoxic CD8 T cell immunity, in line with the results of an ongoing phase-3 heterologous booster trial showing that UB-612 can enhance anti-BA.5 seroconversion rate and viral-neutralizing titer for mRNA, adeno-vectored, and virus-inactivated vaccine platforms. The UB-612 multitope vaccine may serve as an effective primer and booster for those at risk of SARS-CoV-2 infection.
Keywords: Cell biology; Immunity; Microbiology.